Myeloproliferative Neoplasms, version 3.2022, NCCN Clinical Practice Guidelines in Oncology Guidelines


Authors: Gerds, A. T.; Gotlib, J.; Ali, H.; Bose, P.; Dunbar, A.; Elshoury, A.; George, T. I.; Gundabolu, K.; Hexner, E.; Hobbs, G. S.; Jain, T.; Jamieson, C.; Kaesberg, P. R.; Kuykendall, A. T.; Madanat, Y.; McMahon, B.; Mohan, S. R.; Nadiminti, K. V.; Oh, S.; Pardanani, A.; Podoltsev, N.; Rein, L.; Salit, R.; Stein, B. L.; Talpaz, M.; Vachhani, P.; Wadleigh, M.; Wall, S.; Ward, D. C.; Bergman, M. A.; Hochstetler, C.
Title: Myeloproliferative Neoplasms, version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Abstract: The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for the management of MPN in adults. The Guidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.
Keywords: adult; myeloproliferative disorders; myeloproliferative disorder; myeloid metaplasia; primary myelofibrosis; oncology; medical oncology; polycythemia vera; thrombocythemia; thrombocythemia, essential; humans; human
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 20
Issue: 9
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2022-09-01
Start Page: 1033
End Page: 1062
Language: English
DOI: 10.6004/jnccn.2022.0046
PUBMED: 36075392
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 3 October 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Andrew Jeffrey Dunbar
    44 Dunbar